Concepts (277)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dopamine | 19 | 2023 | 245 | 3.290 |
Why?
|
| Mesencephalon | 9 | 2020 | 41 | 2.860 |
Why?
|
| Action Potentials | 12 | 2020 | 231 | 2.420 |
Why?
|
| Neurons | 19 | 2019 | 1175 | 2.330 |
Why?
|
| Substantia Nigra | 8 | 2017 | 44 | 1.770 |
Why?
|
| Ventral Tegmental Area | 9 | 2023 | 36 | 1.530 |
Why?
|
| Cocaine | 6 | 2019 | 232 | 1.400 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2017 | 77 | 1.190 |
Why?
|
| Neural Inhibition | 5 | 2019 | 48 | 1.040 |
Why?
|
| Patch-Clamp Techniques | 10 | 2020 | 223 | 1.030 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 6 | 2018 | 137 | 0.860 |
Why?
|
| Norepinephrine | 5 | 2014 | 110 | 0.860 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 3 | 2015 | 14 | 0.800 |
Why?
|
| Animals | 38 | 2023 | 15081 | 0.800 |
Why?
|
| Nucleus Accumbens | 5 | 2019 | 82 | 0.750 |
Why?
|
| Electrophysiological Phenomena | 3 | 2014 | 19 | 0.680 |
Why?
|
| Avoidance Learning | 1 | 2019 | 62 | 0.650 |
Why?
|
| Choice Behavior | 1 | 2019 | 79 | 0.640 |
Why?
|
| Glycine | 1 | 2018 | 47 | 0.630 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2017 | 12 | 0.600 |
Why?
|
| Endocannabinoids | 2 | 2023 | 39 | 0.590 |
Why?
|
| Long-Term Potentiation | 1 | 2017 | 102 | 0.570 |
Why?
|
| Astrocytes | 1 | 2019 | 255 | 0.560 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2016 | 32 | 0.540 |
Why?
|
| Electrophysiology | 4 | 2012 | 136 | 0.530 |
Why?
|
| Neuronal Plasticity | 2 | 2017 | 103 | 0.510 |
Why?
|
| GABA Antagonists | 5 | 2010 | 29 | 0.510 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2015 | 1618 | 0.500 |
Why?
|
| Synapses | 2 | 2019 | 180 | 0.500 |
Why?
|
| Receptors, Metabotropic Glutamate | 3 | 2004 | 28 | 0.490 |
Why?
|
| Glutamic Acid | 3 | 2019 | 128 | 0.490 |
Why?
|
| Biological Clocks | 4 | 2012 | 53 | 0.480 |
Why?
|
| gamma-Aminobutyric Acid | 5 | 2018 | 79 | 0.450 |
Why?
|
| Motor Activity | 2 | 2019 | 418 | 0.450 |
Why?
|
| Behavior, Animal | 2 | 2014 | 314 | 0.440 |
Why?
|
| Mice | 12 | 2023 | 5913 | 0.440 |
Why?
|
| Rats | 13 | 2011 | 3483 | 0.410 |
Why?
|
| Brain | 3 | 2016 | 1346 | 0.400 |
Why?
|
| Reward | 4 | 2023 | 79 | 0.400 |
Why?
|
| Male | 22 | 2020 | 20025 | 0.370 |
Why?
|
| Receptors, GABA | 1 | 2010 | 25 | 0.360 |
Why?
|
| Receptors, Dopamine D2 | 4 | 2019 | 73 | 0.340 |
Why?
|
| Receptors, GABA-A | 4 | 2010 | 64 | 0.330 |
Why?
|
| Dopamine beta-Hydroxylase | 2 | 2014 | 9 | 0.320 |
Why?
|
| GABA Agonists | 3 | 2010 | 21 | 0.310 |
Why?
|
| Locus Coeruleus | 1 | 2006 | 15 | 0.290 |
Why?
|
| Receptors, AMPA | 3 | 2017 | 56 | 0.290 |
Why?
|
| Female | 15 | 2022 | 20969 | 0.280 |
Why?
|
| Receptors, Glutamate | 2 | 2018 | 27 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 1609 | 0.270 |
Why?
|
| Isonicotinic Acids | 2 | 2010 | 7 | 0.270 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 661 | 0.270 |
Why?
|
| Amphetamine | 2 | 2003 | 16 | 0.250 |
Why?
|
| Synaptic Transmission | 2 | 2006 | 146 | 0.250 |
Why?
|
| Antipsychotic Agents | 2 | 2012 | 68 | 0.230 |
Why?
|
| Mice, Knockout | 5 | 2019 | 933 | 0.220 |
Why?
|
| Klebsiella pneumoniae | 1 | 2022 | 17 | 0.220 |
Why?
|
| Globus Pallidus | 3 | 1999 | 18 | 0.220 |
Why?
|
| Receptors, GABA-B | 4 | 2010 | 11 | 0.220 |
Why?
|
| Milk | 1 | 2022 | 50 | 0.220 |
Why?
|
| Embryonic and Fetal Development | 1 | 2002 | 37 | 0.210 |
Why?
|
| Pregnancy, Animal | 1 | 2002 | 16 | 0.210 |
Why?
|
| Cats | 1 | 2002 | 69 | 0.210 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2002 | 33 | 0.210 |
Why?
|
| Data Interpretation, Statistical | 3 | 2012 | 111 | 0.210 |
Why?
|
| Schizophrenia | 2 | 2012 | 76 | 0.210 |
Why?
|
| Thiazoles | 1 | 2012 | 74 | 0.200 |
Why?
|
| Potassium Channels | 4 | 2010 | 75 | 0.200 |
Why?
|
| Bluetongue | 3 | 2012 | 11 | 0.200 |
Why?
|
| Piperazines | 1 | 2012 | 111 | 0.200 |
Why?
|
| Bluetongue virus | 2 | 2012 | 11 | 0.190 |
Why?
|
| Electrodes, Implanted | 1 | 2020 | 16 | 0.190 |
Why?
|
| Stereotaxic Techniques | 1 | 2020 | 20 | 0.190 |
Why?
|
| Membrane Transport Proteins | 1 | 2001 | 95 | 0.180 |
Why?
|
| Models, Neurological | 2 | 2012 | 128 | 0.180 |
Why?
|
| Picrotoxin | 3 | 2010 | 14 | 0.180 |
Why?
|
| Piperidines | 2 | 2019 | 77 | 0.180 |
Why?
|
| Algorithms | 3 | 2012 | 465 | 0.170 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 211 | 0.170 |
Why?
|
| Amino Acid Transport System X-AG | 1 | 2019 | 11 | 0.170 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 1999 | 99 | 0.170 |
Why?
|
| Steroid 12-alpha-Hydroxylase | 1 | 2018 | 2 | 0.170 |
Why?
|
| Computer Simulation | 2 | 2012 | 362 | 0.170 |
Why?
|
| Organ Culture Techniques | 2 | 2011 | 103 | 0.170 |
Why?
|
| Steroids | 1 | 2018 | 43 | 0.160 |
Why?
|
| Benzamides | 1 | 2019 | 78 | 0.160 |
Why?
|
| Nerve Tissue Proteins | 1 | 2001 | 360 | 0.160 |
Why?
|
| Pyridines | 1 | 2019 | 116 | 0.160 |
Why?
|
| Serotonin | 1 | 2019 | 123 | 0.160 |
Why?
|
| Pedunculopontine Tegmental Nucleus | 1 | 2017 | 1 | 0.160 |
Why?
|
| Locomotion | 2 | 2019 | 97 | 0.160 |
Why?
|
| Raphe Nuclei | 1 | 2017 | 6 | 0.160 |
Why?
|
| Fetus | 2 | 2012 | 105 | 0.150 |
Why?
|
| Neurons, Afferent | 1 | 2017 | 43 | 0.150 |
Why?
|
| Subthalamic Nucleus | 1 | 2017 | 14 | 0.150 |
Why?
|
| Corpus Striatum | 1 | 1999 | 104 | 0.150 |
Why?
|
| Indoles | 1 | 2019 | 158 | 0.150 |
Why?
|
| Time Factors | 3 | 2011 | 1742 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 197 | 0.150 |
Why?
|
| Cattle Diseases | 2 | 2009 | 22 | 0.150 |
Why?
|
| Oxygen | 1 | 2018 | 207 | 0.150 |
Why?
|
| Cyclic GMP | 1 | 2017 | 47 | 0.150 |
Why?
|
| Electric Stimulation | 4 | 2013 | 184 | 0.150 |
Why?
|
| Central Nervous System Stimulants | 1 | 2019 | 174 | 0.150 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2016 | 37 | 0.140 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 2006 | 34 | 0.130 |
Why?
|
| Models, Biological | 1 | 2019 | 677 | 0.130 |
Why?
|
| Microelectrodes | 1 | 2015 | 23 | 0.130 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2015 | 8 | 0.130 |
Why?
|
| Dopamine Agents | 2 | 2013 | 25 | 0.130 |
Why?
|
| Tissue Culture Techniques | 1 | 2015 | 32 | 0.130 |
Why?
|
| Arrestins | 1 | 2014 | 27 | 0.120 |
Why?
|
| Iontophoresis | 2 | 2013 | 10 | 0.120 |
Why?
|
| Hemoglobinopathies | 1 | 2014 | 5 | 0.120 |
Why?
|
| Food Deprivation | 1 | 2013 | 30 | 0.120 |
Why?
|
| Immunoglobulin D | 1 | 2013 | 5 | 0.110 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2013 | 4 | 0.110 |
Why?
|
| Abortion, Veterinary | 1 | 2012 | 2 | 0.110 |
Why?
|
| Normal Distribution | 1 | 2012 | 14 | 0.110 |
Why?
|
| Poisson Distribution | 1 | 2012 | 38 | 0.110 |
Why?
|
| Cattle | 4 | 2022 | 477 | 0.110 |
Why?
|
| Bicuculline | 4 | 1999 | 18 | 0.110 |
Why?
|
| Viral Vaccines | 1 | 2012 | 29 | 0.110 |
Why?
|
| Rats, Wistar | 2 | 2004 | 233 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 664 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2012 | 72 | 0.100 |
Why?
|
| Calcium Signaling | 2 | 2004 | 101 | 0.100 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1207 | 0.100 |
Why?
|
| Baclofen | 3 | 1999 | 8 | 0.100 |
Why?
|
| Evoked Potentials | 2 | 2010 | 87 | 0.100 |
Why?
|
| Obesity | 1 | 2018 | 1067 | 0.090 |
Why?
|
| Animals, Newborn | 1 | 2011 | 343 | 0.090 |
Why?
|
| Aspartic Acid | 2 | 2013 | 47 | 0.090 |
Why?
|
| Calcium | 2 | 2004 | 480 | 0.090 |
Why?
|
| Phosphinic Acids | 2 | 1999 | 3 | 0.090 |
Why?
|
| Propanolamines | 2 | 1999 | 12 | 0.090 |
Why?
|
| Quinpirole | 2 | 2014 | 16 | 0.090 |
Why?
|
| Dopamine Agonists | 2 | 2014 | 30 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 352 | 0.080 |
Why?
|
| Learning | 1 | 2009 | 117 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1039 | 0.080 |
Why?
|
| Cyclic Nucleotide-Gated Cation Channels | 1 | 2007 | 5 | 0.080 |
Why?
|
| Receptors, Dopamine D3 | 2 | 2019 | 12 | 0.070 |
Why?
|
| Autoreceptors | 1 | 2006 | 2 | 0.070 |
Why?
|
| Enkephalin, Methionine | 1 | 2006 | 7 | 0.070 |
Why?
|
| Quinoxalines | 1 | 2006 | 27 | 0.070 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2006 | 39 | 0.070 |
Why?
|
| Humans | 10 | 2022 | 37093 | 0.070 |
Why?
|
| Goat Diseases | 1 | 2005 | 3 | 0.070 |
Why?
|
| Geographic Information Systems | 1 | 2005 | 39 | 0.070 |
Why?
|
| Sheep | 3 | 2012 | 72 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2022 | 201 | 0.060 |
Why?
|
| Ryanodine | 1 | 2004 | 4 | 0.060 |
Why?
|
| Apamin | 1 | 2004 | 8 | 0.060 |
Why?
|
| Intracellular Fluid | 1 | 2004 | 26 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2004 | 35 | 0.060 |
Why?
|
| Phenylephrine | 1 | 2004 | 36 | 0.060 |
Why?
|
| Dopamine Antagonists | 2 | 2019 | 44 | 0.060 |
Why?
|
| Self Administration | 1 | 2004 | 42 | 0.060 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2004 | 48 | 0.060 |
Why?
|
| Interleukin-4 | 1 | 2004 | 72 | 0.060 |
Why?
|
| Caffeine | 1 | 2004 | 28 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2004 | 43 | 0.060 |
Why?
|
| Membrane Potentials | 2 | 2007 | 223 | 0.060 |
Why?
|
| Conditioning, Operant | 1 | 2004 | 73 | 0.060 |
Why?
|
| Potassium | 1 | 2004 | 112 | 0.060 |
Why?
|
| Cocaine-Related Disorders | 1 | 2004 | 85 | 0.060 |
Why?
|
| Amphetamines | 1 | 2003 | 5 | 0.060 |
Why?
|
| Cephalosporins | 1 | 2022 | 3 | 0.060 |
Why?
|
| Aminoglycosides | 1 | 2022 | 6 | 0.060 |
Why?
|
| Carbapenems | 1 | 2022 | 8 | 0.060 |
Why?
|
| Fluoroquinolones | 1 | 2022 | 7 | 0.060 |
Why?
|
| Levodopa | 1 | 2003 | 20 | 0.060 |
Why?
|
| Pregnancy | 2 | 2012 | 1549 | 0.050 |
Why?
|
| beta-Lactamases | 1 | 2022 | 33 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2004 | 234 | 0.050 |
Why?
|
| Extraembryonic Membranes | 1 | 2002 | 6 | 0.050 |
Why?
|
| Long QT Syndrome | 1 | 2012 | 13 | 0.050 |
Why?
|
| Afferent Pathways | 2 | 1999 | 37 | 0.050 |
Why?
|
| Uterus | 1 | 2002 | 55 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 212 | 0.050 |
Why?
|
| Patient Preference | 1 | 2012 | 44 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2002 | 153 | 0.050 |
Why?
|
| Placenta | 1 | 2002 | 97 | 0.050 |
Why?
|
| Carbon-Oxygen Ligases | 1 | 2001 | 1 | 0.050 |
Why?
|
| Enterococcus | 1 | 2001 | 6 | 0.050 |
Why?
|
| Serotyping | 2 | 2012 | 36 | 0.050 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2001 | 50 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2012 | 253 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2003 | 381 | 0.050 |
Why?
|
| Kinetics | 2 | 1999 | 708 | 0.050 |
Why?
|
| Goats | 2 | 2012 | 19 | 0.040 |
Why?
|
| Italy | 2 | 2012 | 22 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 1999 | 22 | 0.040 |
Why?
|
| Electric Impedance | 1 | 1999 | 25 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 1999 | 51 | 0.040 |
Why?
|
| Pyridazines | 1 | 1999 | 14 | 0.040 |
Why?
|
| Receptors, Presynaptic | 1 | 1999 | 4 | 0.040 |
Why?
|
| Amino Acid Transport Systems, Acidic | 1 | 2019 | 2 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 448 | 0.040 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2019 | 40 | 0.040 |
Why?
|
| Morphine | 1 | 2019 | 85 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2001 | 305 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 141 | 0.040 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 1998 | 5 | 0.040 |
Why?
|
| Nerve Degeneration | 1 | 1999 | 107 | 0.040 |
Why?
|
| Fluoxetine | 1 | 1998 | 11 | 0.040 |
Why?
|
| Disease Outbreaks | 2 | 2012 | 155 | 0.040 |
Why?
|
| Axons | 1 | 2019 | 108 | 0.040 |
Why?
|
| Carbon Dioxide | 1 | 1998 | 77 | 0.040 |
Why?
|
| Middle Aged | 4 | 2013 | 10129 | 0.040 |
Why?
|
| Panic Disorder | 1 | 1998 | 100 | 0.040 |
Why?
|
| Prevalence | 2 | 2014 | 1455 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2004 | 905 | 0.040 |
Why?
|
| Papio | 1 | 2016 | 22 | 0.040 |
Why?
|
| Bacterial Proteins | 1 | 2001 | 540 | 0.030 |
Why?
|
| Parkinson Disease, Secondary | 1 | 1996 | 10 | 0.030 |
Why?
|
| Models, Animal | 1 | 2016 | 134 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 142 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2014 | 3 | 0.030 |
Why?
|
| Benzenesulfonates | 1 | 2014 | 8 | 0.030 |
Why?
|
| Chromogranins | 1 | 2014 | 5 | 0.030 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2014 | 7 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 893 | 0.030 |
Why?
|
| Excitatory Amino Acid Agents | 1 | 2013 | 6 | 0.030 |
Why?
|
| Biophysics | 1 | 2013 | 37 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2014 | 107 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 71 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2016 | 587 | 0.030 |
Why?
|
| Buffaloes | 1 | 2012 | 3 | 0.030 |
Why?
|
| Immunization Schedule | 1 | 2012 | 7 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 291 | 0.030 |
Why?
|
| South Africa | 1 | 2012 | 35 | 0.030 |
Why?
|
| Vaccines, Attenuated | 1 | 2012 | 72 | 0.030 |
Why?
|
| Spleen | 1 | 2012 | 199 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2013 | 550 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 137 | 0.030 |
Why?
|
| Adult | 3 | 2012 | 11712 | 0.020 |
Why?
|
| Ion Channel Gating | 1 | 2010 | 83 | 0.020 |
Why?
|
| Calcium Channels | 1 | 2010 | 76 | 0.020 |
Why?
|
| Croatia | 1 | 2009 | 4 | 0.020 |
Why?
|
| Behavior | 1 | 2009 | 32 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2009 | 53 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 1095 | 0.020 |
Why?
|
| Drinking | 1 | 2009 | 38 | 0.020 |
Why?
|
| Maze Learning | 1 | 2009 | 105 | 0.020 |
Why?
|
| Muscimol | 2 | 1999 | 15 | 0.020 |
Why?
|
| Barium Compounds | 1 | 2007 | 2 | 0.020 |
Why?
|
| Salicylamides | 1 | 2007 | 13 | 0.020 |
Why?
|
| Prazosin | 1 | 2007 | 11 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 2007 | 18 | 0.020 |
Why?
|
| Yohimbine | 1 | 2007 | 26 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2007 | 31 | 0.020 |
Why?
|
| Attention | 1 | 2009 | 156 | 0.020 |
Why?
|
| Chlorides | 1 | 2007 | 56 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 562 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2009 | 262 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2012 | 2026 | 0.020 |
Why?
|
| Fear | 1 | 2009 | 249 | 0.020 |
Why?
|
| Animals, Domestic | 1 | 2005 | 8 | 0.020 |
Why?
|
| Animals, Wild | 1 | 2005 | 18 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2005 | 21 | 0.020 |
Why?
|
| Indans | 1 | 2004 | 13 | 0.020 |
Why?
|
| Internet | 1 | 2005 | 211 | 0.010 |
Why?
|
| Teicoplanin | 1 | 2001 | 3 | 0.010 |
Why?
|
| Vancomycin Resistance | 1 | 2001 | 2 | 0.010 |
Why?
|
| Vancomycin | 1 | 2001 | 5 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2001 | 27 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2001 | 22 | 0.010 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2001 | 17 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 99 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 1518 | 0.010 |
Why?
|
| Aged | 2 | 2004 | 6741 | 0.010 |
Why?
|
| Respiratory Mechanics | 1 | 1998 | 27 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 2379 | 0.010 |
Why?
|
| Lactic Acid | 1 | 1998 | 95 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1996 | 481 | 0.010 |
Why?
|